High-Throughput, Low-Cost Detection of SARS-CoV-2 RNA
The SARS-CoV-2 pandemic has created an enormous challenge for laboratories and communities worldwide. With the arrival of flu season, labs are facing unprecedented demands for respiratory viral testing. To address this ongoing crisis, labs require reliable and efficient methods to detect and differentiate between SARS-CoV-2, influenza A, and influenza B viral RNA.
Current detection methods are either too expensive or are constrained by the number of samples that can be processed daily. To meet these challenges, Agena Bioscience® has developed the MassARRAY® SARS-CoV-2 Panel and the MassARRAY SARS-CoV-2/Flu Panel. These panels enable accurate, high-throughput, and low-cost detection of SARS-CoV-2 and influenza.
The MassARRAY SARS-CoV-2/Flu Panel is available for Research Use Only. The MassARRAY SARS-CoV-2 Panel is available for in vitro diagnostic use under Emergency Use Authorization (EUA) from the U.S. FDA and is CE-IVD marked in Europe. For other regions, please visit our Research Use Only Panel.
For in vitro diagnostic use under EUA. CE-IVD marked in Europe.Learn More
High-throughput detection of SARS-CoV-2, Influenza A, and Influenza B RNA.Learn More
Assays by Agena scientists design, develop and functionally verify custom research use assays. Assays can be developed for targeted germline or somatic genotyping, translocations, copy number variants and methylation profiling.